DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Vantas (Histrelin Acetate Implant) - Summary

 
 



VANTAS SUMMARY

Vantas Implant

Vantas™ (histrelin implant) is a sterile non-biodegradable, diffusion-controlled reservoir drug delivery system designed to deliver histrelin continuously for 12 months upon subcutaneous implantation. The Vantas implant contains 50 mg of histrelin acetate. Histrelin acetate is a synthetic nonapeptide analogue of the naturally occurring gonadotropin releasing hormone (GnRH) or luteinizing hormone releasing hormone (LH-RH). The sterile Vantas implantation device (provided with the implant) is used to insert the implant subcutaneously in the inner aspect of the upper arm. After 12 months, the implant must be removed. At the time the implant is removed, another implant may be inserted to continue therapy.

Vantas is indicated in the palliative treatment of advanced prostate cancer .


See all Vantas indications & dosage >>

NEWS HIGHLIGHTS

Media Articles Related to Vantas (Histrelin Implant)

Urologists Dispute Prostate Cancer Screening Recommendation
Source: Medscape Medical News Headlines [2015.05.22]
US Preventive Services Task Force recommendations against prostate screening are among the new payment disagreements arising from the Affordable Care Act and the shift away from fee-for-service.
Medscape Medical News

Scientists unveil prostate cancer's 'Rosetta Stone'
Source: Genetics News From Medical News Today [2015.05.22]
Almost 90 per cent of men with advanced prostate cancer carry genetic mutations in their tumours that could be targeted by either existing or new cancer drugs, a landmark new study reveals.

International study of advanced prostate cancer genome finds potential targets for drug therapy
Source: Genetics News From Medical News Today [2015.05.22]
The first major effort to canvas the genomic landscape of advanced prostate cancer has revealed that many patients may carry some type of genetic abnormality that can be targeted with existing or...

Researchers focus on potential tool for predicting survival, staging prostate cancer
Source: Bones / Orthopedics News From Medical News Today [2015.05.21]
Researchers with the Indiana University School of Medicine have identified a molecule that promotes metastasis of advanced prostate cancer to the bone, an incurable condition that significantly...

Study: MRI Missed 1 in 6 High-Grade Prostate Cancers
Source: Medscape Urology Headlines [2015.05.20]
Men with elevated PSA underwent diagnostic mpMRI and then were double-checked with ultrasound-guided biopsy. The newer tool was not flawless.
Medscape Medical News

more news >>

Published Studies Related to Vantas (Histrelin Implant)

Long-term efficacy and tolerability of once-yearly histrelin acetate subcutaneous implant in patients with advanced prostate cancer. [2011.08.18]
Study Type - Therapy (individual cohort) Level of Evidence 2b What's known on the subject? and What does the study add? Androgen deprivation therapy with a gonadotropin-releasing hormone agonist is an effective option for the palliative treatment of advanced prostate cancer. This study demonstrated the safety and efficacy of the histrelin acetate implant over successive one year treatment cycles for up to four years in an open-label extension trial. OBJECTIVE: * To evaluate the efficacy and tolerability of a once-yearly histrelin implant during an open-label extension of a pivotal study... CONCLUSIONS: * The once-yearly histrelin implant maintained testosterone suppression for repeated treatment cycles and was generally well tolerated. * The histrelin implant provides a clinically attractive option for long-term androgen deprivation therapy in patients with advanced prostate cancer seeking fewer office visits and repeated injections. (c) 2011 THE AUTHORS. BJU INTERNATIONAL (c) 2011 BJU INTERNATIONAL.

Analysis of testosterone suppression in men receiving histrelin, a novel GnRH agonist for the treatment of prostate cancer. [2010.08]
CONCLUSION: The GnRH agonist histrelin successfully suppressed testosterone over the entire study period. This effect was measured across a number of different clinical definitions of PSA response and clinical risk. The GnRH agonist therefore offers an effective therapy option in hormone treatment of prostate cancer.

Free alpha-subunit is the most sensitive marker of gonadotropin recovery after treatment of central precocious puberty with the histrelin implant. [2010.06]
BACKGROUND: Gonadotropin free alpha-subunit (FAS) levels paradoxically increase during GnRH agonist (GnRHa) treatment of central precocious puberty (CPP). The histrelin implant suppresses gonadotropins and estradiol (E(2)) levels for 1 yr, but effects on FAS have not been described. OBJECTIVES: We aimed to determine whether FAS levels remain elevated during treatment with the implant, to assess the dynamics of FAS after removal, and to ascertain the reliability of FAS for monitoring gonadotropin secretion... CONCLUSIONS: Compared to LH, FSH, and E(2), FAS responds more rapidly to implant removal and represents the most sensitive indicator of gonadotropin recovery after histrelin implant treatment.

Histrelin: in advanced prostate cancer. [2010.03.26]
Histrelin is a gonadotropin-releasing hormone agonist available in a diffusion-controlled reservoir drug delivery system for subcutaneous implantation. The subcutaneous histrelin implant provided sustained suppression of serum testosterone, luteinizing hormone (LH) and prostate-specific antigen levels for up to 1 year in patients with advanced prostate cancer in two phase II or III trials...

Drug-induced liver injury caused by the histrelin (Vantus) subcutaneous implant. [2010.01]
Drug-induced liver injury (DILI) is the leading cause of acute hepatic failure in the United States... The case of a patient with liver injury following a subcutaneous histrelin (Vantus) implant as therapy for advanced prostate cancer is presented.

more studies >>

Clinical Trials Related to Vantas (Histrelin Implant)

Prospective Multicentre Non-interventional Study of VANTAS� for the Treatment of Patients With Advanced Prostate Cancer [Recruiting]
The aim of this non-interventional (observational) study is to document, in collaboration with established urologists in Scandinavia, experience gained from routine use of Vantas® for the treatment of patients with advanced prostate cancer. In this observational study particular attention will be directed to treatment duration, quality of life and patient and physician acceptance of the medicinal product for long-term therapy. Patient-based measurement parameters such as quality of life and degree of satisfaction will allow registration of information that extends beyond the clinical parameters. The knowledge gathered will enable patient acceptance of long-term therapy to be evaluated. Clinical outcome will also be documented by measuring serum testosterone and prostate specific antigen (PSA) levels.

Enzalutamide Versus Standard Androgen Deprivation Therapy for the Treatment Hormone Sensitive Prostate Cancer [Not yet recruiting]
This randomized phase II trial compares enzalutamide with standard androgen deprivation therapy in reducing incidence of metabolic syndrome in patients with prostate cancer that has spread to other places in the body. Metabolic syndrome is defined as changes in cholesterol, blood pressure, circulating sugar levels, and body weight. Previous studies have shown that patients with prostate cancer, who have been treated with standard medical therapy that lowers testosterone levels, have an increased risk of these changes. Hormone therapy using enzalutamide may fight prostate cancer by blocking the use of testosterone by the tumor cells instead of lowering testosterone levels. It is not yet known whether prostate cancer patients who receive enzalutamide will have reduced incidence of metabolic syndrome than patients who receive standard androgen deprivation therapy.

more trials >>


Page last updated: 2015-05-22

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2015